Effects of Obex in Overweight and Obese Patients
Effects of Obex in Overweight and Obese Patients
-  Obesity is an important and growing public health worldwide

 -  Obesity is highly related to the development of metabolic syndrome, diabetes,
 cardiovascular diseases and cancer

 -  An extensive body of evidence from efficacy trials has shown that weight loss is
 achievable, however, a modest weight loss is achieved in a small proportion of patients

 -  Important adverse events have been reported with the use of antiobesity drugs.

 -  The use of natural products with potential effects inducing weight loss is an
 alternative strategy for treating patients with overweight and obesity. However,
 efficacy and safety should be evaluated in RCT.

 -  Obex combines different molecules with potential effects inducing weight loss and
 control on metabolic parameters such as fasting glucose, cholesterol and triglycerides.

 -  Therefore, the administration of Obex in overweight and obese patients with impaired
 fasting glucose could be an excellent strategy to induce weight loss and ameliorate the
 metabolic disturbances related to obesity and overweight.
Inclusion Criteria:

 -  Overweight and Obese subjects with and without IFG

 -  Ability to provide informed consent

 Exclusion Criteria:

 -  Presence of diabetes mellitus, hepatic, renal or cardiovascular disease

 -  Other diseases associated with insulin resistance (eg. Acromegalia, endogenous
 hypercortisolism, etc)

 -  Sepsis or any other condition that could potentially interfere with treatment

 -  History of bariatric surgery

 -  Pregnancy or lactation

 -  Concomitant disease with reduced life expectancy

 -  Severe psychiatric conditions

 -  Anyone with chronic medical conditions requiring regular intake of any prescription
 medications.

 -  Used drugs for weight loss (e.g., Xenical [orlistat], Meridia [sibutramine], Acutrim
 [phenylpropanolamine], Accomplia [rimonabant], Alli [low-dose orlistat], or other
 similar over-the-counter weight loss remedies or medications) within 3 months of
 screening

 -  Are actively participating in, or have participated in a formal weight loss program
 within the last 3 months